


# Novel therapies and technologies

- Any technology not currently used in veterinary medicines
- Nanotechnology
- Bacteriophages
- Gene therapy
- Cell-based therapy
- ...?




### Nanotechnology

- Substances at nanometer scale, with particular properties because of nanoscale dimensions.
- Nanoantibiotics. Nanostructures may act synergistically with antibiotics
- Nanoparticles as delivery systems or adjuvants for vaccines
- Nanoparticles as targeted drug delivery systems
- Nanosensors, for earlier or more accurate detection of disease or infection



## Bacteriophages

 Particular viruses that infect only Bacteria and have the ability to kill their host



## Bacteriophages

Bacteria and bacteriophages are in a continuous evolutionary arms race.

- Bacteriophages force bacteria into defensive action (which may weaken them in other areas)
- Bacteria adapt to combat infection by phages
- New bacteriophage variants evolve...etc.



# Application of bacteriophages

- bacteriophages are applied in humans and animals with some success
  - Often only to specific patients, for a limited time
  - wider application may be possible
- Complete cure of an infection may not always be the goal:
  - decontamination (of the environment or of feed/food)
  - use in conjunction with antibiotics (enhancing the susceptibility of bacteria)



# Genetherapy in veterinary medicine

### **Potential future targets:**

- inherited diseases/genetic defects (i.e. ocular, metabolic)
- wound healing
- Fertility regulation
- chronic diseases (osteoarthritis, diabetes, <u>allergy</u>, renal, ocular) and neoplasms




# Novel Therapies and technologies Working Party

### Regulation (EU) 2019/6

"Taking into account the specificities of novel therapy products, specific requirements additional to the standard requirements for evaluation of quality, safety and efficacy may be appropriate."



### Novel Therapies and technologies Working Party



#### **NTWP**

Guidelines to be developed (subject, scope) Horizon scanning Supervise work of the OEGs

#### **Operational Expert Groups**

OEG for each topic experts in veterinary and human field; from academia, institutions, national authorities

Guidance published after approval by CVMP: Used by developers and the authorities

### Recent / future Guidance by NTWP

 Development and data requirements of potency tests for cell-based therapy products and the relation to clinical efficacy (published)

 Quality, safety and efficacy of bacteriophages as veterinary medicines (final stages prior to publication)

• Safety of nanomedicines (early stages: concept paper under development)

Thank you for your attention!

